SIREN : 354036501
UNIPHARM LOIRE-OCEAN is a French company founded 36 years ago, specialized in the sector Centrales d'achat non alimentaires. Based in BASSE-GOULAINE (44115), this company of category PME shows in 2024 a revenue of 7.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7 012 897 € | 6 427 332 € | 7 322 076 € | 5 190 694 € | 5 181 717 € | 3 429 494 € | 3 235 442 € | 2 773 625 € | 2 508 813 € |
| Net income | 1 718 293 € | 1 562 791 € | 1 428 311 € | 1 174 013 € | 1 010 482 € | 169 474 € | 183 475 € | 111 569 € | 94 604 € |
| EBITDA | 1 861 693 € | 1 706 129 € | 1 528 827 € | 1 246 739 € | 1 100 029 € | 248 126 € | 265 150 € | 176 376 € | 137 774 € |
| Net margin | 24.5% | 24.3% | 19.5% | 22.6% | 19.5% | 4.9% | 5.7% | 4.0% | 3.8% |
In 2024, UNIPHARM LOIRE-OCEAN achieves revenue of 7.0 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +13.7%. Vs 2023: +9%. After deducting consumption (4.1 M€), gross margin stands at 2.9 M€, i.e. a rate of 42%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.9 M€, representing 26.5% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.7 M€, i.e. 24.5% of revenue. This profit can be retained or distributed to shareholders.
7 012 897 €
2 917 586 €
1 861 693 €
1 782 400 €
1 718 293 €
26.5%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 72%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 24.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
72.026%
24.871%
0.0
54.8%
In 2024, the debt ratio of UNIPHARM LOIRE-OCEAN (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of UNIPHARM LOIRE-OCEAN (72.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of UNIPHARM LOIRE-OCEAN (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 357.43. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
357.434
0.0
In 2024, the liquidity ratio of UNIPHARM LOIRE-OCEAN (357.43) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of UNIPHARM LOIRE-OCEAN (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 95 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 67 days. The company must finance 28 days of gap between collections and payments. Inventory turnover is 35 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 130 days of revenue, i.e. 2.5 M€ to permanently finance. Over 2016-2024, WCR increased by +393%, requiring additional financing.
2 526 256 €
95 j
67 j
35 j
130 j
Based on 85 transactions of similar company sales
(all years),
the value of UNIPHARM LOIRE-OCEAN is estimated at
2 067 736 €
(range 1 106 514€ - 8 094 977€).
With an EBITDA of 1 861 693€, the sector multiple of 1.0x is applied.
The price/revenue ratio is 0.32x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare UNIPHARM LOIRE-OCEAN with other companies in the same sector:
Voir toutes les statistiques du secteur Centrales d'achat non alimentaires
The revenue of UNIPHARM LOIRE-OCEAN in 2024 is 7.0 M€.
Yes, UNIPHARM LOIRE-OCEAN generated a net profit of 1.7 M€ in 2024.
The headquarters of UNIPHARM LOIRE-OCEAN is located in BASSE-GOULAINE (44115), in the department Loire-Atlantique.
The tax return of UNIPHARM LOIRE-OCEAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
UNIPHARM LOIRE-OCEAN operates in the sector Centrales d'achat non alimentaires (NAF code 46.19A). See the 'Sector positioning' section above to compare the company with its competitors.